NHL-BFM Study Center, Department of Pediatric Hematology and Oncology, Justus Liebig University, Giessen, Germany.
Leukemia. 2011 Jan;25(1):153-60. doi: 10.1038/leu.2010.245. Epub 2010 Oct 29.
Age-related differences in the distribution, biology and treatment response of non-Hodgkin's lymphoma (NHL) in adolescents remain to be elucidated. The current analyses present clinical parameters and outcomes of adolescents treated in pediatric NHL-BFM trials. Patients were stratified by histological subtype: lymphoblastic lymphoma (LBL); mature B-NHL, including Burkitt's lymphoma/leukemia (BL/B-AL), diffuse B-cell lymphoma (DLBCL-CB) and mediastinal B-cell lymphoma (PMLBL); and anaplastic large cell lymphoma (ALCL). Between October 1986 and December 2007, 2915 patients were registered, including 378 (13%) adolescents (15-18 years) with BL/B-AL (n=101), ALCL (n=74), DLBCL-CB (n=55), T-LBL (n=45), PMLBL (n=24), pB-LBL (n=13) and rare or not-specified NHL subtypes (n=66). The 5-year event-free survival (EFS) was 79±2% for adolescents compared with 85±1% for patients aged <15 years (P=0.014). EFS was 83±7% for adolescents with T-LBL, 82±4% with BL/B-AL, 85±5% with DLBCL-CB, 57±10% with PMLBL and 70±6% with ALCL. According to sex, the 5-year EFS in females versus males, respectively, was 70±5 versus 83±2% overall (P=0.004), 57±17 versus 92±6% (P=0.0036) for T-LBL patients and 71±9 versus 97±3% (P=0.0067) for DLBCL-CB patients. Adolescents with NHL treated according to pediatric NHL-BFM protocols had an EFS of 79±2%, which is marginally inferior to that of children. In adolescents with T-LBL and DLBCL-CB, female sex was associated with a worse prognosis.
青少年非霍奇金淋巴瘤（NHL）的分布、生物学和治疗反应的年龄相关差异仍有待阐明。目前的分析介绍了在儿科 NHL-BFM 试验中治疗的青少年的临床参数和结果。患者按组织学亚型分层：淋巴母细胞淋巴瘤（LBL）；成熟 B-NHL，包括伯基特淋巴瘤/白血病（BL/B-AL）、弥漫性 B 细胞淋巴瘤（DLBCL-CB）和纵隔 B 细胞淋巴瘤（PMLBL）；间变性大细胞淋巴瘤（ALCL）。1986 年 10 月至 2007 年 12 月，共登记了 2915 例患者，其中 378 例（13%）为青少年（15-18 岁），包括 BL/B-AL（n=101）、ALCL（n=74）、DLBCL-CB（n=55）、T-LBL（n=45）、PMLBL（n=24）、pB-LBL（n=13）和罕见或未指定 NHL 亚型（n=66）。与年龄<15 岁的患者（85±1%）相比，青少年的 5 年无事件生存率（EFS）为 79±2%（P=0.014）。T-LBL 患者的 5 年 EFS 为 83±7%，BL/B-AL 为 82±4%，DLBCL-CB 为 85±5%，PMLBL 为 57±10%，ALCL 为 70±6%。按性别划分，女性与男性的 5 年 EFS 分别为 70±5%和 83±2%（整体）（P=0.004）、T-LBL 患者的 57±17%和 92±6%（P=0.0036）和 DLBCL-CB 患者的 71±9%和 97±3%（P=0.0067）。根据儿科 NHL-BFM 方案治疗的青少年 NHL 患者的 EFS 为 79±2%，略低于儿童患者。在 T-LBL 和 DLBCL-CB 患者中，女性性别与预后较差相关。
